KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Total Debt (2016 - 2023)

Pacific Biosciences Of California (PACB) has 12 years of Total Debt data on record, last reported at $96.2 million in Q3 2023.

  • For Q3 2023, Total Debt changed N/A year-over-year to $96.2 million; the TTM value through Sep 2023 reached $96.2 million, changed N/A, while the annual FY2022 figure was $172.1 million, N/A changed from the prior year.
  • Total Debt reached $96.2 million in Q3 2023 per PACB's latest filing, down from $186.3 million in the prior quarter.
  • Across five years, Total Debt topped out at $186.3 million in Q2 2023 and bottomed at $15.8 million in Q4 2019.
  • Average Total Debt over 3 years is $131.0 million, with a median of $172.1 million recorded in 2022.
  • The widest YoY moves for Total Debt: up 7.78% in 2019, down 7.78% in 2019.
  • A 3-year view of Total Debt shows it stood at $15.8 million in 2019, then surged by 989.2% to $172.1 million in 2022, then crashed by 44.1% to $96.2 million in 2023.
  • Per Business Quant database, its latest 3 readings for Total Debt were $96.2 million in Q3 2023, $186.3 million in Q2 2023, and $184.4 million in Q1 2023.